BioRestorative Therapies ... (BRTX)
BioRestorative Therapies Statistics
Share Statistics
BioRestorative Therapies has 7.5M shares outstanding. The number of shares has increased by 2.22% in one year.
| Shares Outstanding | 7.5M |
| Shares Change (YoY) | 2.22% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 3.47% |
| Shares Floating | 5.43M |
| Failed to Deliver (FTD) Shares | 4.54K |
| FTD / Avg. Volume | 1.17% |
Short Selling Information
The latest short interest is 329.69K, so 4.76% of the outstanding shares have been sold short.
| Short Interest | 329.69K |
| Short % of Shares Out | 4.76% |
| Short % of Float | 5.84% |
| Short Ratio (days to cover) | 6.68 |
Valuation Ratios
The PE ratio is -1.24 and the forward PE ratio is -2.11. BioRestorative Therapies's PEG ratio is 0.02.
| PE Ratio | -1.24 |
| Forward PE | -2.11 |
| PS Ratio | 27.69 |
| Forward PS | 0.1 |
| PB Ratio | 1.3 |
| P/FCF Ratio | -1.35 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for BioRestorative Therapies.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.97, with a Debt / Equity ratio of 0.
| Current Ratio | 2.97 |
| Quick Ratio | 2.97 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $36.45K |
| Profits Per Employee | $-816.31K |
| Employee Count | 11 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 21.53% in the last 52 weeks. The beta is 0.36, so BioRestorative Therapies's price volatility has been higher than the market average.
| Beta | 0.36 |
| 52-Week Price Change | 21.53% |
| 50-Day Moving Average | 1.82 |
| 200-Day Moving Average | 1.7 |
| Relative Strength Index (RSI) | 48.45 |
| Average Volume (20 Days) | 387.24K |
Income Statement
In the last 12 months, BioRestorative Therapies had revenue of 401K and earned -8.98M in profits. Earnings per share was -1.16.
| Revenue | 401K |
| Gross Profit | 372.93K |
| Operating Income | -11.56M |
| Net Income | -8.98M |
| EBITDA | -11.56M |
| EBIT | -11.56M |
| Earnings Per Share (EPS) | -1.16 |
Balance Sheet
The company has 547.89K in cash and 0 in debt, giving a net cash position of 547.89K.
| Cash & Cash Equivalents | 547.89K |
| Total Debt | 0 |
| Net Cash | 547.89K |
| Retained Earnings | -155.68M |
| Total Assets | 12.28M |
| Working Capital | 7.4M |
Cash Flow
In the last 12 months, operating cash flow was -8.23M and capital expenditures 0, giving a free cash flow of -8.23M.
| Operating Cash Flow | -8.23M |
| Capital Expenditures | 0 |
| Free Cash Flow | -8.23M |
| FCF Per Share | -1.06 |
Margins
Gross margin is 93%, with operating and profit margins of -2881.59% and -2239.25%.
| Gross Margin | 93% |
| Operating Margin | -2881.59% |
| Pretax Margin | -2239.25% |
| Profit Margin | -2239.25% |
| EBITDA Margin | -2881.59% |
| EBIT Margin | -2881.59% |
| FCF Margin | -2052.46% |
Dividends & Yields
BRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BRTX is $18, which is 928.6% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18 |
| Price Target Difference | 928.6% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Oct 27, 2021. It was a backward split with a ratio of 1:4000.
| Last Split Date | Oct 27, 2021 |
| Split Type | backward |
| Split Ratio | 1:4000 |
Scores
| Altman Z-Score | -17.95 |
| Piotroski F-Score | 3 |